Effects of Psychiatric Disorders and Psychotropic Medications on Prolactin and Bone Metabolism

Journal of Clinical Psychiatry

Volumn 65, Issue 12, 2004, Pages 1607-1618

  Misra, Madhusmita ^a,b   Papakostas, George I ^a   Klibanski, Anne ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; LITHIUM; PROLACTIN; PSYCHOTROPIC AGENT;

ADULT; BIPOLAR DISORDER; BLOOD; BONE; BONE DENSITY; CHEMICALLY INDUCED DISORDER; COMORBIDITY; COMPARATIVE STUDY; DEPRESSION; DRUG EFFECT; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; MAJOR DEPRESSION; MALE; MENTAL DISEASE; METABOLISM; OSTEOPOROSIS; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

ADULT; ANTICONVULSANTS; BIPOLAR DISORDER; BONE AND BONES; BONE DENSITY; COMORBIDITY; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; HYPERPROLACTINEMIA; HYPOGONADISM; LITHIUM; MALE; MENTAL DISORDERS; OSTEOPOROSIS; PROLACTIN; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA;

EID: 13744257121     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n1205     Document Type: Review

References (160)

1. Halbreich U, Rojansky N, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995;57:485-491
2. Abraham G, Friedman R, Verghese C, et al. Osteoporosis and schizophrenia: can we limit known risk factors? [letter] Biol Psychiatry 1995; 38:131-132
3. Delva N, Crammer J, Jarzylo S, et al. Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia. Biol Psychiatry 1989;26:781-793 (Pubitemid 20016478)
4. Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Engl J Med 1996;335:1176-1181 (Pubitemid 26339771)
5. Schweiger U, Deuschle M, Korner A, et al. Low lumbar bone mineral density in patients with major depression. Am J Psychiatry 1994;151: 1691-1693 (Pubitemid 24337605)
6. Schweiger U, Weber B, Deuschle M, et al. Lumbar bone mineral density in patients with major depression: evidence of increased bone loss at follow-up. Am J Psychiatry 2000;157:118-120 (Pubitemid 30027431)
7. Misra M, Klibanski A. Evaluation and treatment of low bone density in anorexia nervosa. Nutr Clin Care 2002;5:298-308
8. Grinspoon S, Herzog D, Klibanski A. Mechanisms and treatment options for bone loss in anorexia nervosa. Psychopharmacol Bull 1997;33: 399-404 (Pubitemid 27430602)
9. Grinspoon S, Thomas E, Pitts S, et al. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med 2000;133:790-794 (Pubitemid 30839973)
10. Soyka L, Misra M, Frenchman A, et al. Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2002; 87:4177-4185
11. Mazess R, Barden H, Ettinger M, et al. Bone density of the radius, spine, and proximal femur in osteoporosis. J Bone Miner Res 1988;3:13-18 (Pubitemid 18210521)
12. Canuso C, Goldstein J, Wojcik J, et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 2002;111:11-20 (Pubitemid 34879071)
13. Huber T, Rollnik J, Wilhelms J, et al. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 2001;26:27-35 (Pubitemid 30818111)
14. Riggs B. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 2000;106:1203-1204 (Pubitemid 30943944)
15. Goff D, Henderson D, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992;149:1189-1194
16. Baastrup P, Christiansen C, Transbol I. Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy. Neuropsychobiology 1980;6:56-59 (Pubitemid 10136170)
17. Meaney A, Smith S, Howes O, et al. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004;184:503-508 (Pubitemid 38725710)
18. Durham R, Johnson J, Eaton M, et al. Opposing roles for dopamine D1 and D2 receptors in the regulation of hypothalamic tuberoinfundibular dopamine neurons. Eur J Pharmacol 1998;355:141-147 (Pubitemid 28404696)
19. Tuomisto J, Mannisto P. Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 1985;37:249-332 (Pubitemid 16107648)
20. Wieck A, Haddad P. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: selective literature review. Br J Psychiatry 2003;182:199-204 (Pubitemid 36286731)
21. Greenspan S, Neer R, Ridgway E, et al. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 1986;104:777-782 (Pubitemid 16115040)
22. Greenspan S, Oppenheim D, Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 1989;110:526-531 (Pubitemid 19097320)
23. Di Somma C, Colao A, Di Sarno A, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998;83:807-813 (Pubitemid 28496451)
24. Klibanski A, Neer R, Beitins I, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med 1980;303:1511-1514 (Pubitemid 11178981)
25. Klibanski A, Biller B, Rosenthal D, et al. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988; 67:124-130 (Pubitemid 18177127)
26. Biller B, Baum H, Rosenthal D, et al. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992;75:692-697
27. Koppelman M, Kurtz D, Morrish K, et al. Vertebral body bone mineral content in hyperprolactinemic women. J Clin Endocrinol Metab 1984; 59:1050-1053 (Pubitemid 15223335)
28. Schlechte J, Sherman B, Martin R. Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 1983; 56:1120-1123
29. Colao A, Di Somma C, Loche S, et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 2000;52:319-327 (Pubitemid 30169688)
30. Petty R. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999;35(suppl):S67-S73 (Pubitemid 29133027)
31. Cara J. Growth hormone in adolescence: normal and abnormal. Endocrinol Metab Clin North Am 1993;22:533-552 (Pubitemid 23298887)
32. Ohlsson C, Bengtsson B, Isaksson O, et al. Growth hormone and bone. Endocr Rev 1998;19:55-79 (Pubitemid 29122074)
33. Bachrach L. Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol Metab 2001;12:22-28 (Pubitemid 33713182)
34. Lindsay R. The effect of sex steroids on the skeleton in premenopausal women. Am J Obstet Gynecol 1992;166(6 pt 2):1993-1996
35. Lindsay R, Cosman F. Skeletal effects of estrogen analogs. Osteoporos Int 1997;7(suppl 1):S40-S42 (Pubitemid 27183349)
36. Klibanski A, Greenspan S. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 1986;315:542-546 (Pubitemid 16014768)
37. Meaney A, O'Keane V. Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci 2002;71:979-992 (Pubitemid 34667104)
38. Nestores J, Lehmann H, Ben T. Neuroleptic drugs and sexual function in schizophrenics. Mod Probl Pharmacopyschiatry 1980;15:111-130
39. Kuruvilla A, Peedicayil J, Srikrishna G, et al. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 1992;19:603-606
40. Kinon B, Gilmore J, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28(suppl 2):55-68 (Pubitemid 36332229)
41. Nordstrom A, Farde L. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 1998;18:305-310 (Pubitemid 28353873)
42. Gruen P, Sachar E, Langer G, et al. Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 1978;35: 108-116 (Pubitemid 8263443)
43. Meltzer H, Fang V. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976;33:279-286
44. Smith S, Wheeler M, Murray R, et al. The effects of antipsychoticinduced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002;22:109-114 (Pubitemid 34289384)
45. Meltzer H, Busch D, Fang V. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 1983;9: 271-283
46. Rivera J, Lal S, Ettigi P, et al. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 1976;5:273-282
47. Laughren T, Brown W, Williams B. Serum prolactin and clinical state during neuroleptic treatment and withdrawal. Am J Psychiatry 1979; 136:108-110 (Pubitemid 9085124)
48. Igarashi Y, Higuchi T, Toyoshima R, et al. Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia. Adv Biochem Psychopharmacol 1985;40:95-98
49. Kolakowska T, Braddock L, Wiles D, et al. Neuroendocrine tests during treatment with neuroleptic drugs, 1: plasma prolactin response to haloperidol challenge. Br J Psychiatry 1981;139:400-404
50. Zelaschi N, Delucchi G, Rodriguez J. High plasma prolactin levels after long-term neuroleptic treatment. Biol Psychiatry 1996;39:900-901 (Pubitemid 26163537)
51. Polishuk W, Kulcsar S. Effects of chlorpromazine on pituitary function. J Clin Endocrinol Metab 1956;16:292-293
52. Magharious W, Goff D, Amico E. Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Res 1998;77:159-166 (Pubitemid 28157267)
53. Smith S, O'Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002;181:49-55 (Pubitemid 34717838)
54. Ghadirian A, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982;170:463-467 (Pubitemid 12051650)
55. Windgassen K, Wesselmann U, Schulze Monking H. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology 1996;33:142-146 (Pubitemid 26156190)
56. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci 2000;68: 29-39
57. Kearns A, Goff D, Hayden D, et al. Risperidone-associated hyperprolactinemia. Endocr Pract 2000;6:425-429
58. Henderson DC, Goff DC, Connolly CE, et al. Risperidone added to clozapine: impact on serum prolactin levels. J Clin Psychiatry 2001; 62:605-608 (Pubitemid 32848163)
59. Turrone P, Kapur S, Seeman M, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159:133-135
60. Becker D, Liver O, Mester R, et al. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003;64:761-766 (Pubitemid 36897211)
61. Potkin S, Saha A, Kujawa M, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60:681-690 (Pubitemid 36818630)
62. Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004;65:57-61
63. Masi G, Cosenza A, Mucci M, et al. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003;64:1039-1047 (Pubitemid 37158249)
64. Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 2003;64:1362-1369 (Pubitemid 37490243)
65. Kleinberg D, Davis J, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19:57-61 (Pubitemid 29047332)
66. Bobes J, Garc A-Portilla M, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003;29:125-147 (Pubitemid 36278732)
67. Zhang X, Zhou D, Yuan C, et al. Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. Psychiatry Res 2002;109:297-302 (Pubitemid 34311986)
68. Tollin S. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 2000;23:765-770 (Pubitemid 32041058)
69. Cohen L, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 2001;11:435-440 (Pubitemid 34117293)
70. Schlosser R, Grunder G, Anghelescu I, et al. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002;46:33-40 (Pubitemid 35002316)
71. Tran P, Hamilton S, Kuntz A, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418 (Pubitemid 27414397)
72. Tollefson G, Beasley CJ, Tran P, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465 (Pubitemid 27147597)
73. Crawford A, Beasley CJ, Tollefson G. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26:41-54 (Pubitemid 27372056)
74. Kim K-S, Pae C-U, Chae J-H, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002;63:408-413 (Pubitemid 34507218)
75. Kapur S, Roy P, Daskalakis J, et al. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 2001;158:311-314
76. Wudarsky M, Nicolson R, Hamburger S, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999;9:239-245 (Pubitemid 30005078)
77. Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002;63:992-997 (Pubitemid 35388057)
78. Arvanitis L, Miller B, for the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
79. Goff D, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18: 296-304 (Pubitemid 28353872)
80. Knegtering R, Castelein S, Bous H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 2004;24:56-61 (Pubitemid 38139316)
81. Keller R, Mongini F. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. Neurol Sci 2002;23:233-235 (Pubitemid 36024567)
82. Takahashi H, Higuchi H, Kamata M, et al. Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea. J Neuropsychiatry Clin Neurosci 2003;15:375-377 (Pubitemid 36999384)
83. Goodnick P. Ziprasidone: profile on safety. Expert Opin Pharmacother 2001;2:1655-1662 (Pubitemid 33019733)
84. Weiden P, Daniel D, Simpson G, et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003;23:595-600 (Pubitemid 37443191)
85. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002;302:1129-1134 (Pubitemid 34920235)
86. Devlin M, Yanovski S, Wilson G. Obesity: what mental health professionals need to know. Am J Psychiatry 2000;157:854-866 (Pubitemid 30412334)
87. Stigler K, Potenza M, Posey D, et al. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr Drugs 2004;6:33-44 (Pubitemid 38295123)
88. Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 2003;23(3 suppl 1):S21-S26 (Pubitemid 36807784)
89. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002;63:425-433 (Pubitemid 34507221)
90. Sernyak M, Leslie D, Alarcon R, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566 (Pubitemid 34274937)
91. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63:920-930 (Pubitemid 35231733)
92. Gianfrancesco F, White R, Wang R, et al. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003;23:328-335 (Pubitemid 36951173)
93. Koro C, Fedder D, L'Italien G, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243-247 (Pubitemid 34864389)
94. Fuller M, Shermock K, Secic M, et al. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003;23:1037-1043 (Pubitemid 36904003)
95. Caro JJ, Ward A, Levinton C, et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002;63:1135-1139 (Pubitemid 36084058)
96. Lindenmayer J, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-296 (Pubitemid 41110454)
97. Melkersson K, Dahl M. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64:701-723 (Pubitemid 38471372)
98. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-865 (Pubitemid 35231725)
99. Ataya K, Mercado A, Kartaginer J, et al. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril 1988;50:876-881 (Pubitemid 19017956)
100. Bilici M, Cakirbay H, Guler M, et al. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 2002;112:817-828 (Pubitemid 34890661)
101. Abraham G, Paing W, Kaminski J, et al. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry 2003;160:1618-1620 (Pubitemid 41079547)
102. Whooley M, Simon G. Managing depression in medical outpatients. N Engl J Med 2000;343:1942-1950 (Pubitemid 32064789)
103. Gold P, Goodwin F, Chrousos G. Clinical and biochemical manifestations of depression: relation to the neurobiology of stress, 1. N Engl J Med 1988;319:348-353 (Pubitemid 18190889)
104. Robbins J, Hirsch C, Whitmer R, et al. The association of bone mineral density and depression in an older population. J Am Geriatr Soc 2001; 49:732-736 (Pubitemid 32652465)
105. Yazici K, Akinci A, Sutcu A, et al. Bone mineral density in premenopausal women with major depressive disorder. Psychiatry Res 2003; 117:271-275 (Pubitemid 36398502)
106. Coelho R, Silva C, Maia A, et al. Bone mineral density and depression: a community study in women. J Psychosom Res 1999;46:29-35 (Pubitemid 29030507)
107. Herran A, Amado J, Garcia-Unzueta M, et al. Increased bone remodeling in first-episode major depressive disorder. Psychosom Med 2000; 62:779-782 (Pubitemid 32009083)
108. Deuschle M, Blum W, Strasburger C, et al. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997;22:493-503 (Pubitemid 27505109)
109. Deuschle M, Schweiger U, Weber B, et al. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 1997;82:234-238 (Pubitemid 27021303)
110. Zelissen P, Croughs R, van Rijk P, et al. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 1994;120:207-210 (Pubitemid 24038804)
111. Kleerekopper M, Schiebinger R. Skeletal recovery after treatment of Cushing's: still room for improvement. J Clin Endocrinol Metab 1995; 80:2856-2858
112. Leong G, Mercado-Asis L, Reynolds J, et al. The effect of Cushing's disease on bone mineral density, body composition, growth, and puberty: a report of an identical adolescent twin pair. J Clin Endocrinol Metab 1996;81:1905-1911 (Pubitemid 26152484)
113. Nielsen H, Brixen K, Kassem M, et al. Inhibition of the morning cortisol peak abolishes the expected morning decrease in serum osteocalcin in normal males: evidence of a controlling effect of serum cortisol on the circadian rhythm in serum osteocalcin. J Clin Endocrinol Metab 1992;74:1410-1414
114. Penninx B, Kritchevsky S, Yaffe K, et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry 2003;54:566-572
115. Steptoe A, Kunz-Ebrecht S, Owen N. Lack of association between depressive symptoms and markers of immune and vascular inflammation in middle-aged men and women. Psychol Med 2003;33:667-674 (Pubitemid 36626048)
116. Kagaya A, Kugaya A, Takebayashi M, et al. Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology 2001;43:59-62 (Pubitemid 32149726)
117. Grinspoon S, Miller K, Coyle C, et al. Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab 1999;84:2049-2055 (Pubitemid 30647032)
118. Michelson D, Galliven E, Hill L, et al. Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. J Clin Endocrinol Metab 1997;82:2601-2606 (Pubitemid 27337880)
119. Sonntag A, Rothe B, Guldner J, et al. Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression 1996;4: 1-13 (Pubitemid 26386328)
120. Wiegand M, Berger M. Action of trimipramine on sleep and pituitary hormone secretion. Drugs 1989;38(suppl 1):35-42 (Pubitemid 19282890)
121. Overtoom C, Verbaten M, Kemner C, et al. Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder. Behav Brain Res 2003; 145:7-15 (Pubitemid 37188627)
122. Jarrett D, Pollock B, Miewald J, et al. Acute effect of intravenous clomipramine upon sleep-related hormone secretion in depressed outpatients and healthy control subjects. Biol Psychiatry 1991;29:3-14
123. Jarrett D, Miewald J, Kupfer D. Acute changes in sleep-related hormone secretion of depressed patients following oral imipramine. Biol Psychiatry 1988;24:541-554 (Pubitemid 18195552)
124. Muck-Seler D, Pivac N, Sagud M, et al. The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1235-1243 (Pubitemid 35341573)
125. Slater S, Lipper S, Shiling D, et al. Elevation of plasma-prolactin by monoamine-oxidase inhibitors. Lancet 1977;2:275-276
126. Scheinin M, Koulu M, Karhuvaara S, et al. Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers. Life Sci 1990;47: 1491-1499
127. Laakmann G, Schule C, Baghai T, et al. Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 1999;24:769-784 (Pubitemid 29378503)
128. Schule C, Baghai T, Bidlingmaier M, et al. Endocrinological effects of mirtazapine in healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1253-1261 (Pubitemid 35341575)
129. Hemrick-Luecke S, Fuller R. Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212. Eur J Pharmacol 1996;311:207-211 (Pubitemid 26330376)
130. Li Q, Levy A, Cabrera T, et al. Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5-HT1A agonist, 8-OH-DPAT, in male rats. Brain Res 1993;630:148-156 (Pubitemid 23342836)
131. Pan L, Gilbert F. Activation of 5-HT1A receptor subtype in the paraventricular nuclei of the hypothalamus induces CRH and ACTH release in the rat. Neuroendocrinology 1992;56:797-802 (Pubitemid 23099551)
132. Li Q, Rittenhouse P, Levy A, et al. Neuroendocrine responses to the serotonin2 agonist DOI are differentially modified by three 5-HT1A agonists. Neuropharmacology 1992;31:983-989
133. Levy A, Li Q, Rittenhouse P, et al. Investigation of the role of 5-HT3 receptors in the secretion of prolactin, ACTH and renin. Neuroendocrinology 1993;58:65-70
134. Herdman J, Delva N, Hockney R, et al. Neuroendocrine effects of sumatriptan. Psychopharmacology (Berl) 1994;113:561-564 (Pubitemid 24150511)
135. Seletti B, Benkelfat C, Blier P, et al. Serotonin1A receptor activation by flesinoxan in humans: body temperature and neuroendocrine responses. Neuropsychopharmacology 1995;13:93-104
136. von Bardeleben U, Steiger A, Gerken A, et al. Effects of fluoxetine upon pharmacoendocrine and sleep-EEG parameters in normal controls. Int Clin Psychopharmacol 1989;4(suppl 1):1-5
137. Seifritz E, Baumann P, Muller M, et al. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males: a placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 1996;14:253-263 (Pubitemid 126335724)
138. Seifritz E, Muller M, Annen O, et al. Effect of sleep deprivation on neuroendocrine response to a serotonergic probe in healthy male subjects. J Psychiatry Res 1997;31:543-554 (Pubitemid 27443115)
139. Spigset O, Mjorndal T. The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status. J Clin Psychopharmacol 1997;17:292-297 (Pubitemid 27312428)
140. Raap D, Van de Kar L. Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci 1999;65:1217-1235 (Pubitemid 29425959)
141. Peterson M. Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin Proc 2001;76:215-216 (Pubitemid 32126060)
142. Morrison J, Remick R, Leung M, et al. Galactorrhea induced by paroxetine [letter]. Can J Psychiatry 2001;46:88-89
143. Bonin B, Vandel P, Sechter D, et al. Paroxetine and galactorrhea. Pharmacopsychiatry 1997;30:133-134 (Pubitemid 27362083)
144. Lesaca T. Sertraline and galactorrhea [letter]. J Clin Psychopharmacol 1996;16:333-334
145. Bronzo M, Stahl S. Galactorrhea induced by sertraline [letter]. Am J Psychiatry 1993;150:1269-1270
146. Plenge P, Rafaelsen O. Lithium effects on calcium, magnesium and phosphate in man: effects on balance, bone mineral content, faecal and urinary excretion. Acta Psychiatr Scand 1982;66:361-373
147. Mak T, Shek C, Chow C, et al. Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. J Clin Endocrinol Metab 1998;83:3857-3859 (Pubitemid 28513562)
148. Nordenstrom J, Elvius M, Bagedahl-Strindlund M, et al. Biochemical hyperparathyroidism and bone mineral status in patients treated longterm with lithium. Metabolism 1994;43:1563-1567 (Pubitemid 24382709)
149. Cohen O, Rais T, Lepkifker E, et al. Lithium carbonate therapy is not a risk factor for osteoporosis. Horm Metab Res 1998;30:594-597 (Pubitemid 28459624)
150. Haden S, Stoll A, McCormick S, et al. Alterations in parathyroid dynamics in lithium-treated subjects. J Clin Endocrinol Metab 1997;82:2844-2848 (Pubitemid 27385637)
151. De Rosa G, Testa A, Giacomini D, et al. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for nontoxic goitre. Clin Endocrinol (Oxf) 1997;47:529-535 (Pubitemid 27496327)
152. Jodar E, Begona Lopez M, Garcia L, et al. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass. Osteoporos Int 1998;8: 311-316 (Pubitemid 28418264)
153. Bauer M, Whybrow P. Rapid cycling bipolar affective disorder, 2: treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990;47:435-440
154. Hurowitz G, Liebowitz M. Antidepressant-induced rapid cycling: six case reports. J Clin Psychopharmacol 1993;13:52-56 (Pubitemid 23030360)
155. Ertugrul A, Meltzer H. Antipsychotic drugs in bipolar disorder. Int J Neuropsychopharmacol 2003;6:277-284 (Pubitemid 37248006)
156. Sheth R, Wesolowski C, Jacob J, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-262
157. Kafali G, Erselcan T, Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr (Phila) 1999;38:93-98 (Pubitemid 29086791)
158. Feldkamp J, Becker A, Witte O, et al. Long-term anticonvulsant therapy leads to low bone mineral density: evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000;108:37-43 (Pubitemid 30160433)
159. Farhat G, Yamout B, Mikati M, et al. Effect of antiepileptic drugs on
160. Abraham G, Friedman R, Verghese C. Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients [letter]. Biol Psychiatry 1996;40:430-431